News & Updates

Resistance to antipsychotic treatment may result in worse cognitive function among patients with schizophrenia, with disorganization, doses, and negative symptoms playing a major role in this association, according to a Singapore study.

In the treatment of patients with rifampicin-resistant tuberculosis (TB), two bedaquiline-containing regimens, namely a 9-month all-oral regimen and a shorter 6-month regimen with 8 weeks of aminoglycoside, maintains superior efficacy to a 9-month injectable regimen through 132 weeks, according to long-term data from the STREAM 2 trial.

Narrowband ultraviolet B (NB-UVB) phototherapy or light therapy performed at home is as good as one done in the doctor’s office in patients with plaque and guttate psoriasis, as shown in the randomized Light Treatment Effectiveness (LITE) trial presented at EADV 2024.

In the treatment of moderate-to-severe psoriasis, patients with overweight or obesity appear to have a diminished response to vunakizumab compared with those who have lower BMIs, according to a post hoc subgroup analysis of a phase III trial.

A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.